Numerous studies have shown that Hsp90 inhibition in myeloma cells induces apoptosis and depletes multiple client proteins such as AKT, STAT3, IL-6Rα, thereby simultaneously disrupting multiple pathways known to contribute to cell survival, including the JAK/STAT, PI3K, NF-κβ, and RAS/ERK pathways [169]. Here, HSP90AB1 is linked to plasma cell myeloma.